TMEM272: A Non-Coding RNA Molecule as A Potential Drug Target for Cancer

Target Name: TMEM272

NCBI ID: G283521

TMEM272: A Non-Coding RNA Molecule as A Potential Drug Target for Cancer

TMEM272 (NCRNA00282) is a non-coding RNA molecule that has been identified as a potential drug target (or biomarker) for the treatment of various diseases, including cancer. TMEM272 is a transcription factor that can bind to DNA and regulate gene expression . Its structural domain consists of an N-terminal 伪-helix, a C-terminal 尾-coil, and two central 尾-stacks. TMEM272 has variable expression levels in various cancers and has shown potential as a potential therapeutic target.

TMEM272 was first discovered in human breast, lung, and prostate cancers. Studies have shown that the expression level of TMEM272 is significantly different in these cancer tissues, and the expression level of TMEM272 is positively correlated with the aggressiveness and prognosis of cancer. In addition, the expression level of TMEM272 is also related to the molecular mechanisms of various cancers, such as EMT (extracellular transport) and MET (extracellular membrane transport) of tumor cells.

In addition, TMEM272 is also associated with the clinical manifestations of a variety of diseases. For example, the expression level of TMEM272 is negatively correlated with the survival rate of breast cancer patients, and the expression level of TMEM272 is also positively correlated with the survival rate of lung cancer patients. In addition, the expression level of TMEM272 is also positively correlated with the survival rate of prostate cancer patients.

The structure and functional domains of TMEM272 suggest that it may be a potential drug target. Intervention targeting TMEM272 may help improve the survival rate and quality of life of cancer patients. Therefore, TMEM272 is a drug target worthy of further study and is expected to bring better therapeutic effects to cancer patients.

Protein Name: Transmembrane Protein 272

More Common Targets